{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:04:03Z","timestamp":1762859043269,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Basic Science Research Program through the National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1I1A3A0403710411"],"award-info":[{"award-number":["2021R1I1A3A0403710411"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Probenecid (PBN) is a uricosuric agent that facilitates the excretion of uric acid and is used to treat gout. Here, a colon-targeted prodrug of PBN was designed to facilitate repositioning as a treatment for inflammatory bowel disease (IBD). Methods: The carboxylic group in PBN was amide-conjugated with the amine groups of acidic amino acids to yield aspartic acid-conjugated PBN (PBN-AA) and glutamic acid-conjugated PBN (PBN-GA). Conjugation with amino acids increased the hydrophilicity of PBN and decreased cell permeability across the Caco-2 cell monolayer. While remaining intact in buffers (pH 1.2, 6.8) and in the small intestinal contents of rats, the conjugates were cleaved to release PBN from the cecal contents of rats, with a significant difference in the maximal conversion percentage between PBN-AA (12%) and PBN-GA (74%). Results: Upon oral gavage, PBN-GA accumulated a much greater amount of PBN in the cecum than PBN alone, thus verifying the in vitro colon specificity of PBN-GA. Oral PBN-GA enhanced the anticolitis effectiveness in dinitrobenzene sulfonic acid-induced rat colitis and limited the systemic absorption of PBN, thus reducing the risk of systemic adverse effects ascribed to PBN. Moreover, PBN-GA therapeutically surpassed sulfasalazine, a currently used anti-IBD drug, in rat colitis. Conclusions: These results suggest that amide conjugation with GA can be used to design a colon-targeting prodrug for PBN. Colon-targeted PBN may not only enhance therapeutic effectiveness but also improve the safety of PBN repositioned for the treatment of IBD and may be a pharmacological alternative for current small-molecule anti-IBD drugs with low efficacy or serious adverse effects with long-term use.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111454","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:56:27Z","timestamp":1762858587000},"page":"1454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Colon-Specific Delivery of Probenecid Enhances Therapeutic Activity of the Uricosuric Agent Against Rat Colitis"],"prefix":"10.3390","volume":"17","author":[{"given":"Yeonhee","family":"Jeong","sequence":"first","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea"},{"name":"Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaejeong","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea"},{"name":"Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyu","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea"},{"name":"Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjin","family":"Jung","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea"},{"name":"Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2174\/13816128113199990416","article-title":"Inflammatory bowel disease: Etiology, pathogenesis and current therapy","volume":"20","author":"Ko","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1734-1140(11)70575-8","article-title":"Treatment of inflammatory bowel disease (IBD)","volume":"63","author":"Pithadia","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/00365521.2014.968864","article-title":"Conventional drug therapy for inflammatory bowel disease","volume":"50","author":"Bryant","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Imbrizi, M., Magro, F., and Coy, C.S.R. (2023). Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091272"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13543784.2022.2032639","article-title":"JAK inhibitors in crohn\u2019s disease: Ready to go?","volume":"31","author":"Gabbiadini","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The History and Future of Probenecid","volume":"12","author":"Robbins","year":"2011","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rusiecka, O.M., Tournier, M., Molica, F., and Kwak, B.R. (2022). Pannexin1 channels\u2014A potential therapeutic target in inflammation. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1020826"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10753-015-0230-1","article-title":"Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis","volume":"39","author":"Hainz","year":"2015","journal-title":"Inflammation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"C761","DOI":"10.1152\/ajpcell.00227.2008","article-title":"Probenecid, a gout remedy, inhibits pannexin 1 channels","volume":"295","author":"Silverman","year":"2008","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Rodr\u00edguez, C., Mujica, P., Illanes-Gonz\u00e1lez, J., L\u00f3pez, A., Vargas, C., S\u00e1ez, J.C., Gonz\u00e1lez-Jamett, A., and Ardiles, \u00c1.O. (2023). Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061516"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nature09413","article-title":"Pannexin 1 channels mediate \u2018find-me\u2019 signal release and membrane permeability during apoptosis","volume":"467","author":"Chekeni","year":"2010","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbamcr.2016.10.006","article-title":"Pannexin1 as mediator of inflammation and cell death","volume":"1864","author":"Willebrords","year":"2017","journal-title":"Biochim. Biophys. Acta BBA-Mol. Cell Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jones, L.P., Martin, D.E., Murray, J., Sancilio, F., and Tripp, R.A. (2025). Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs). Biomolecules, 15.","DOI":"10.3390\/biom15040511"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18143","DOI":"10.1074\/jbc.M109.004804","article-title":"The pannexin 1 channel activates the inflammasome in neurons and astrocytes","volume":"284","author":"Silverman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Diezmos, E.F., Markus, I., Perera, D.S., Gan, S., Zhang, L., Sandow, S.L., Bertrand, P.P., and Liu, L. (2018). Blockade of Pannexin-1 Channels and Purinergic P2X7 Receptors Shows Protective Effects Against Cytokines-Induced Colitis of Human Colonic Mucosa. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00865"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nm.2679","article-title":"Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis","volume":"18","author":"Gulbransen","year":"2012","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17425240903490401","article-title":"What should be considered on design of a colon-specific prodrug?","volume":"7","author":"Jung","year":"2010","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i2.20","article-title":"Therapeutic opportunities in colon-specific drug-delivery systems","volume":"24","author":"Patel","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/acs.molpharmaceut.0c01228","article-title":"Preparation and Evaluation of Colon-Targeted Prodrugs of the Microbial Metabolite 3-Indolepropionic Acid as an Anticolitic Agent","volume":"18","author":"Lee","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1021\/acs.molpharmaceut.9b00872","article-title":"5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity","volume":"17","author":"Jeong","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/acs.molpharmaceut.2c00255","article-title":"A Colon-Targeted Prodrug of Riluzole Improves Therapeutic Effectiveness and Safety upon Drug Repositioning of Riluzole to an Anti-Colitic Drug","volume":"19","author":"Park","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/1871520620666200811124013","article-title":"Design, synthesis and studies on novel polymeric prodrugs of erlotinib for colon drug delivery","volume":"21","author":"Kumar","year":"2021","journal-title":"Anti-Cancer Agents Med. Chem.-Anti-Cancer Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/1061186X.2015.1128941","article-title":"Polysaccharide-based micro\/nanocarriers for oral colon-targeted drug delivery","volume":"24","author":"Zhang","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1021\/acs.molpharmaceut.9b00664","article-title":"Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation","volume":"16","author":"Kim","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198600321-00003","article-title":"Sulphasalazine: A Review of 40 Years\u2019 Experience","volume":"32","author":"Watkinson","year":"1986","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kim, J., Kang, C., Yoo, J.W., Yoon, I.S., and Jung, Y. (2023). N-Succinylaspartic-Acid-Conjugated Riluzole Is a Safe and Potent Colon-Targeted Prodrug of Riluzole against DNBS-Induced Rat Colitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15112638"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/mp200591q","article-title":"Colon-targeted cell-permeable NFkappaB inhibitory peptide is orally active against experimental colitis","volume":"9","author":"Hong","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s10787-024-01532-w","article-title":"Combinatorial intervention with dental pulp stem cells and sulfasalazine in a rat model of ulcerative colitis","volume":"32","author":"Aly","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.3748\/wjg.v26.i35.5272","article-title":"New approach of medicinal herbs and sulfasalazine mixture on ulcerative colitis induced by dextran sodium sulfate","volume":"26","author":"Shin","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e007148","DOI":"10.1161\/JAHA.117.007148","article-title":"Probenecid improves cardiac function in patients with heart failure with reduced ejection fraction in vivo and cardiomyocyte calcium sensitivity in vitro","volume":"7","author":"Robbins","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3904\/kjim.2022.132","article-title":"Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-\u03b1","volume":"37","author":"Park","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1023\/A:1011033121528","article-title":"Colonic drug delivery: Prodrug approach","volume":"18","author":"Sinha","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5001\/omj.2010.24","article-title":"Colon targeted drug delivery systems: A review on primary and novel approaches","volume":"25","author":"Philip","year":"2010","journal-title":"Oman Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Seo, J.H., Dalal, M.S., and Contreras, J.E. (2021). Pannexin-1 channels as mediators of neuroinflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105189"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Feng, J., Cao, W., Wang, Z., Xu, B., Li, G., and Li, M. (2025). Leucine and glutamic acid attenuate the dextran sulfate sodium-induced colitis in mice by modulating the inflammatory response and energy metabolism processes. J. Nutr. Biochem., 145.","DOI":"10.1016\/j.jnutbio.2025.110016"},{"key":"ref_39","first-page":"685","article-title":"Drug repurposing for cardiovascular diseases: New targets and indications for probenecid","volume":"180","author":"Koch","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jama.1966.03110150075021","article-title":"Long-term effect of probenecid on diuretic-induced hyperuricemia","volume":"198","author":"Freis","year":"1966","journal-title":"JAMA"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:00:54Z","timestamp":1762858854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111454"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111454","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}